DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Telmisartan, Amlodipine and Flow Mediated Dilation

Information source: Johannes Gutenberg University Mainz
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Telmisartan (Drug); Amlodipine (Drug); Olmesartan medoxomil (Drug); Hydrochlorothiazide (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Johannes Gutenberg University Mainz

Official(s) and/or principal investigator(s):
Stefan Blankenberg, Prof.Dr.med., Principal Investigator, Affiliation: Universitätsmedizin Mainz, II.Medizinische Klinik

Summary

To show superior effects of the combination Telmisartan and Amlodipine (T and A) vs Olmesartan and Hydrochlorothiazide (O and HCTZ) on endothelial dysfunction as measured by flow mediated dilation (FMD) in hypertensive at risk patients beyond bloodpressure BP (equal BP in both arms; target BP <140/90 mmHg (<130/80 mmHg for renally impaired and/ or diabetic patients). To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness and carotid atherosclerotic plaques.

Clinical Details

Official title: A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

FMD flow mediated dilation

FMD

Secondary outcome:

Echogenicity

arterial stiffness

arterial stiffness

Echogenicity

Detailed description: This is a Phase IV, randomised, double-blind, forced- titration, active controlled, mono-center study to primarily compare the effects on endothelial function of the combination of telmisartan and amlodipine versus olmesartan and hydrochlorothiazide in hypertensive patients at risk beyond blood pressure. Additionally, key secondary endpoints for this trial are the changes in plaque and intima media complex echogenicity and the change in arterial stiffness after 26 weeks of treatment. 576 patients will be included in the study after a screening period of two weeks and then randomised in one of the two treatment groups. Pretreatment with ARBs, ACE-Inhibitors, amlodipine and diuretics will be stopped last day before visit 2. At visit 2 the treatment with either telmisartan and amlodipine or olmesartan and hydrochlorothiazide starts, so that no medication is stopped without having been replaced by the study medication. After two weeks treatment all patients will be up-titrated and having the maintenance dose for the following 24 weeks. The trial will be performed at one center in Germany with access to patients with hypertension. Patients will be recruited from the Department of Cardiology of the university Mainz. There will be a promotion flyer and an information booklet about the study for cardiologists practicising near Mainz, who like to sent their patient to the study center. Sponsor of the trial is the university Mainz. Stefan Blankenberg, MD has been designated as Principal Investigator for this national, mono-center trial. The study will be completed when the last patient had his last visit and the telephone

follow - up two weeks later will be performed. This latest patient contact is defined as end

of trial.

Eligibility

Minimum age: 35 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Ability to provide written informed consent in accordance with Good Clinical Practice

and local legislation.

- Age 35 and older.

- Male and female, treated and treatment-naive patients with uncontrolled hypertension

(defined as 20/10 mmHg above target BP of <140/90 mmHg [<130/80 mmHg for renally impaired and/ or diabetics patients])

- Male and female treated patients with controlled hypertension (defined as target BP <

140/90 mmHg [ < 130/80 mmHg for renally impaired and/ or diabetics patients])

- > 3 cardiovascular risk factors CVRFs and/or metabolic syndrome and/or diabetes

mellitus and/or end organ damage Exclusion Criteria: 1. Pretreatment with Telmisartan within the last 3 months. 2. Pretreatment with Amlodipine, Diuretics and AT1Blocker/ACEInhibitor within the last 3 months 3. Myocardial infarction within last 6 months. 4. Previous stroke or hemodynamically relevant stenosis of carotic arteria (>70%). 5. Previous cardial or peripheral bypass surgery within last 6 months.

6. PAD stadium III - IV n. F.

7. Chronic heart failure NYHA III- IV. 8. Unstable angina. 9. Known intolerance to angiotensin receptor blockers, diuretics or dihydropyridine calcium channel blocker. 10. Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who: 1. are not surgically sterile; or 2. are nursing, or 3. are pregnant, or 4. are of childbearing potential and are NOT practicing acceptable methods of birth control, or do NOT plan to continue practicing an acceptable method throughout the trial. The only acceptable methods of birth control are: 5. Intra-Uterine Device (IUD) 6. Oral 7. implantable or injectable contraceptives 8. Estrogen patch 9. Hormonal birth control should have been in use for at least three months before the study and continue at least until the next menstrual period after completing the study 11. Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4: 00 a. m. 12. Known or suspected secondary hypertension (e. g., renal artery stenosis or phaeochromocytoma) 13. Mean in-clinic seated cuff SBP ≥180 mmHg and/or DBP ≥110 mmHg 14. Renal dysfunction as defined by the following laboratory parameters: 15. Serum creatinine >3. 0 mg/dL (or >265 μmol/L) and/or known estimated creatinine clearance of <30 ml/min and/or clinical markers of severe renal impairment. 16. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney 17. Clinically relevant hypokalemia or hyperkalemia (i. e., <3. 0 or >5. 5 mEq/L, may be rechecked for suspected error in result) 18. Uncorrected sodium or volume depletion 19. Primary aldosteronism 20. Hereditary fructose intolerance 21. Biliary obstructive disorders (e. g., cholestasis) or hepatic insufficiency 22. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator 23. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve 24. Patients whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥10% 25. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists 26. History of drug or alcohol abuses within six months prior to signing the informed consent form 27. Concomitant administration of any medications known to affect BP, except medications allowed by the protocol 28. Any investigational drug therapy within one month of signing the informed consent 29. Known contraindication to any component of the trial drugs (telmisartan, amlodipine, olmesartan, hydrochlorothiazide) 30. History of non-compliance or inability to comply with prescribed medications or protocol procedures 31. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication

Locations and Contacts

Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz 55131, Germany
Additional Information

Starting date: August 2010
Last updated: July 11, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017